<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

NANS 2019: Highlights and Key Takeaways

Posted by Anne Staylor on 5/7/19 7:30 AM

SmartTRAK highlights key takeaways from the recent North American Neuromodulation (NANS) 22nd annual meeting held in Las Vegas in January, including important company news, trials, technologies, and trends affecting the US market for spinal cord stimulation (SCS) and what's next in this market. This informative article also includes exclusive interviews with leading figures in Neuromodulation including Saluda Medical CEO John Parker, President Abbott Neuromodulation Keith Boetigger, Medtronic Senior VP and Pain Therapies President Marshall Stanton, and Medtronic Senior Global Product Manager for Pain Stimulation and Early Interventions Brian Ranck ...

Spotlight on Saluda Medical

In one of the most anticipated presentations at NANS 2019, Nagy Mekail, MD, PhD presented preliminary three-month results from Saluda Medical’s EVOKE US pivotal RCT (N=134), which is evaluating Saluda’s ECAP-controlled, closed-loop, Evoke SCS System. In the double-blinded study, the experimental arm (n=67) received closed-loop Evoke stimulation while the control arm (n=67) received fixed-output, open-loop Evoke SCS stimulation. At three months, the closed-loop group demonstrated superiority (Ps=0.005) having an 82.3% (51/62) success rate vs the open-loop group’s 60.3% (38/63) in 50% or greater reduction in overall Trunk and Limb VAS. The closed-loop group also met superiority (Ps=0.003) in terms of low back pain responders at three months with 80.6% demonstrating a 50% or greater reduction in back VAS versus 57.1% in the open-loop group. Of note, the closed loop Evoke group spent 91.1% of time (median % of stimuli) within the therapeutic window vs 59.5% of the time in the open-loop group.

In another presentation, Charles Brooker, MBChB presented updated results from the ongoing AVALON trial evaluating the safety and performance of 

Read More

Topics: Neuromodulation-Spinal Cord Stimulation

Q418/FY18 Market Recap: SCS Market Slows

Posted by Anne Staylor on 4/9/19 10:12 AM

The Spinal Cord Stimulation (SCS) market saw high-teens growth in FY18, but decelerated in Q418.

The US SCS Market saw another banner year in FY18, growing +17.4% YoY. Market growth was driven by new product launches, expanding indications and ongoing demand for non-narcotic alternatives that address chronic intractable pain and the opioid epidemic.

Read More

Topics: Neuromodulation-Spinal Cord Stimulation

Q318 SCS Market Recap: On Track for Another Record Year

Posted by Anne Staylor on 1/21/19 10:17 AM

New Products, Continued Demand Provide SCS Market Tailwinds

SmartTRAK reports that with new products providing a strong tailwind in Q318, the SCS market saw another quarter of strong double-digit growth in both the US and WW, positioning the market for another record year. 

Among the many topics covered in the Q318 SCS Market Recap are:

Read More

Topics: Neuromodulation-Spinal Cord Stimulation, Q318 Market Recaps

Spinal Cord Stimulation: Top Trends to Watch in 2019 and Beyond

Posted by Anne Staylor on 1/15/19 12:00 PM

SmartTRAK identifies trends to watch in spinal cord stimulation 

With the start of a new year, it's time to look back at 2018 and identify continuing and emerging trends in the market for Spinal Cord Stimulation (SCS) that are likely to shape the landscape in 2019 and beyond.

So what’s on the horizon? Anne Staylor, SmartTRAK Managing Editor, gives her predictions for the top technology and market trends to watch.

Among the many interesting and informative topics covered in the article are:

Read More

Topics: Neuromodulation-Spinal Cord Stimulation

An Interview with Medtronic's Matt Thomas

Posted by Anne Staylor on 11/6/18 11:00 AM

Medtronic’s Matt Thomas discusses the Company’s strategies for driving growth in spinal cord stimulation and plans for innovation in an interview with SmartTRAK at ASIPP 2018.

Matt Thomas, General Manager and Vice President of Medtronic’s STIM & Early Intervention business discusses the Company’s growth strategies, plans for innovation, and what’s next in spinal cord stimulation in a podcast interview with SmartTRAK at the American Society of Interventional Pain Physicians (ASIPP) 2018 held March 15-17, 2018 in Orlando, FL

Click the Podcast Link to hear the interview, recorded live at ASIPP 2018. (18:55 minutes.)

To receive a downloadable transcript, click the button below...

Read More

Topics: Neuromodulation-Spinal Cord Stimulation, SmartTRAK Interviews

SmartTRAK Publication Alert: US Spinal Cord Stimulation Market Recap

Posted by Anne Staylor on 6/25/18 11:32 PM

SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its Q118 US Spinal Cord Stimulation Market Recap.

The US Spinal Cord Stimulation (SCS) market saw another quarter of exceptional growth in Q118, yet the market decelerated QoQ, posting 23% growth vs 24.6% growth in Q417. While seasonal trends were behind the QoQ slowdown ...

Among the many topics covered in the full Q118 SCS Market Recap are: 

Read More

Topics: Neuromodulation-Spinal Cord Stimulation

A Look Back: The One to Beat, Nevro's Growth Strategies and Challenges

Posted by Anne Staylor on 6/18/18 4:37 PM

In May 2017, Nevro CEO Rami Elghandour chatted with Anne Staylor, BioMedGPS Managing Editor/Neuro Analyst to discuss dynamics in the global spinal cord stimulation (SCS) market, including trends, drivers, challenges, competition, and opportunity that would influence the Company’s growth. 

A fascinating read then, that now has us appraising a year later if Elghandour's expansion predictions came to pass. Is Nevro still the one to beat as the top leader in the neuromodulation field?

Register to download PDF or read the interview in full below!

Read More

Topics: Neuromodulation, Neurotherapies, Neuromodulation-Spinal Cord Stimulation

Strategies in Stroke Care:  Interview with Medtronic's Stacey Pugh

Posted by Anne Staylor on 6/11/18 2:28 PM

Medtronic’s Stacey Pugh discusses the Company’s new Riptide Aspiration System, new products in development, and growth strategies for the neurovascular business in a podcast interview with SmartTRAK at the International Stroke Conference (ISC) 2018 held Jan. 24-26, 2018 in Los Angeles, CA.

Anne Staylor here with BioMedGPS. We're at the International Stroke Conference in Los Angeles, and today I'm talking with Stacey Pugh of Medtronic Neurovascular. Hi Stacey, thanks for joining me.

Read More

Topics: Neuromodulation-Spinal Cord Stimulation

phenox Aiming To Bring Novel Stroke Devices to the US Market

Posted by Anne Staylor on 6/8/18 3:52 PM

In the market for stroke devices, Europe seems to be the proving ground for next generation devices, and several companies with novel technologies are emerging from Europe that could potentially reach the US market in the next several years. One European company taking aim at the US market is Bochum, Germany-based phenox GmbH.

Read More

Topics: Neuromodulation-Spinal Cord Stimulation, SmartTRAK Interviews

SmartTRAK'S Final 2017 Spinal Cord Stimulation Market Financial Results

Posted by Anne Staylor on 4/9/18 12:27 PM

The US Spinal Cord Stimulation market reached new heights in Q417/FY17, driven by new products, expanding indications, and a growing demand for non-narcotic alternatives for treating chronic intractable pain. 

SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 US Spinal Cord Stimulation Market Recap and Financial Dashboard.

Among the many topics covered in the Q417/FY17 Spinal Cord Stimulation Market Recap are:

Read More

Topics: Neuromodulation-Spinal Cord Stimulation

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts